-
-
-
-
-
-
-
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
-
-
-
-
-
-
-
ARS Pharmaceuticals Inc (SPRY) PT Raised to $32 at Raymond James
-
-
-
-
-
-
-
ARS Pharmaceuticals, Inc. (SPRY) Misses Q2 EPS by 1c
-
-
-
-
-
-
-
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
-
-
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

